by admin | 4 June 2024 | News
NEW YORK, June 4, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal... by admin | 30 May 2024 | News
NEW YORK, May 30, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of... by admin | 13 May 2024 | News
NEW YORK, May 13, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has submitted an FDA request to obtain...
by admin | 5 May 2024 | Media
“One of the common problems we see in our clinic is that often patients continue to get worse clinically, but there are no changes on their MRI. In other words, we don’t know the reason why patients are getting worse, despite having no new lesions or relapses.”... by admin | 25 April 2024 | News
NEW YORK, April 25, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time, quantitative data...
by admin | 24 April 2024 | Media
Link to original article: Foralumab eases fatigue in most SPMS patients in access program (multiplesclerosisnewstoday.com) Foralumab found to ease fatigue in SPMS patients in access program Use of nasal spray reduced levels after 6 months in 7 of 10 patients in EAP by... by admin | 23 April 2024 | News
NEW YORK, April 23, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration... by admin | 22 April 2024 | News
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-up All Patients Have Either Stabilized or Improved on Foralumab Treatment and No Patients Declined in Key Clinical Measures NEW...
by admin | 22 April 2024 | Media
Foralumab’s anti-CD3 mechanism modulates T cell function, offering potential benefits for the challenging-to-treat na-SPMS patients. Link to original article: Nasal Foralumab Shows Attenuation of Microglial Activation, Clinical Stabilization in Non-Active... by admin | 19 April 2024 | News
– Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) — Data presented in a platform session at the Annual Meeting of the American Academy... by admin | 18 April 2024 | News
– Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans – NEW YORK, April 18, 2024 – Tiziana Life Sciences, Ltd....
by admin | 18 April 2024 | Media
Link to original article: Neurology Today (lww.com) The fully human anti-CD3 antibody foralumab attenuates microglial activation in patients with non-active secondary progressive multiple sclerosis (na-SPMS) with progression independent of relapse (PIRA), according... by admin | 11 April 2024 | News
NEW YORK, April 11, 2024 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral presentation, titled, “Treatment of PIRA with...
by admin | 5 April 2024 | Media
Six months of treatment with foralumab, administered into the nose, led to decreases in microglial activity in five of six people with nonactive secondary progressive multiple sclerosis (SPMS) involved in an expanded access program. Microglia are resident immune cells...
by admin | 5 April 2024 | Media
Significant Improvements in Progressive Multiple Sclerosis Through Foralumab Treatment Link to original article: Significant Improvements in Progressive Multiple Sclerosis Through Foralumab Treatment (neurologylive.com) Over a 6-month treatment period, investigators... by admin | 5 March 2024 | News
Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD) Nasal anti-CD3 reduced hemorrhage and edema that occurs with ARIA based on animal studies Neuroinflammation modulation... by admin | 8 January 2024 | News
NEW YORK, January 08, 2024 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight... by admin | 5 January 2024 | News
NEW YORK, January 5, 2024 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew... by admin | 5 January 2024 | News
NEW YORK, January 5, 2024 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition and methods... by admin | 19 December 2023 | News
NEW YORK, December 19, 2023 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase 2a study comparing two...
by admin | 9 December 2023 | Media
Alzheimer’s disease (AD) has a new candidate for its treatment. Nasal anti-CD3 monoclonal antibody (MAb) reduced microglia activation in the brain of mice without its effect being dependent on the β-amyloid (Aβ) deposits characteristic of this neurodegenerative... by admin | 30 November 2023 | News
NEW YORK, November 30, 2023 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the company has successfully... by admin | 10 November 2023 | News
Late-breaking poster to be presented titled: “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes” NEW YORK, October 11, 2023 — Tiziana Life Sciences Ltd. (Nasdaq:... by admin | 18 October 2023 | News
Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing Initiative Greater Than 1 year Safety Exposure to anti-CD3 Foralumab Has Been Well-Tolerated At-Home Dosing Likely to...
